Showing 1881-1890 of 2038 results for "".
- Zeiss Launches Virtual Optometry Hubhttps://modernod.com/news/zeiss-launches-virtual-optometry-hub/2478226/Zeiss announced it is launching the Zeiss Virtual Optometry Hub on September 20-21. In the all-new 360° experience, visitors will be able to take a walk through the Zeiss Virtual Practice and see how diagnostic equipment and data management can integrate seamlessly to provide a sophisticated prac
- Genentech Initiates Phase 3 Trial for Port Delivery System with Ranibizumab in Diabetic Retinopathyhttps://modernod.com/news/late-stage-trial-starts-for-port-delivery-system-with-ranibizumab-in-diabetic-retinopathy/2478224/Genentech has initiated a new phase 3 clinical trial investigating Port Delivery System with ranibizumab (PDS) for people with diabetic retinopathy (DR). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of r
- PDL BioPharma Files With SEC For Potential Spin-Off of Lensarhttps://modernod.com/news/pdl-biopharma-announces-filing-of-a-form-10-registration-statement-with-the-sec-for-a-potential-spin-off-of-lensar-to-pdls-stockholders/2478207/PDL BioPharma announced that its majority owned medical device subsidiary, Lensar, has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) relating to a potential spin-off of Lensar from PDL. “Preparations for a spin-off of Lensar to PDL’
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- New Evidence Suggests Young Children Spread COVID-19 More Efficiently Than Adultshttps://modernod.com/news/new-evidence-suggests-young-children-spread-covid-19-more-efficiently-than-adults/2478128/Two new studies, though from different parts of the world, have arrived at the same conclusion: that young children not only transmit SARS-CoV-2 efficiently, but may be major drivers of the pandemic as well, according to a Forbes
- Face-to-Face Meetings Between Pharma and Doctors Are On the Uphttps://modernod.com/news/face-to-face-meetings-between-pharma-and-doctors-are-on-the-up/2478102/Second-quarter results reported to date by large-cap pharmaceutical and biotech companies illustrate that social distancing measures weighed heavily on topline drug revenues in April and May. In addition to slowing patient access to medicines, the COVID-19 pandemic has also forced the industry to
- Algorithm Compares Risk of Cancelled Ophthalmology Appointments Against COVID-19https://modernod.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/The COVID-19 pandemic has forced many ophthalmologists across the US to cancel potentially necessary eye examinations with patients since March. A team, led by Nikhil K. Bommakanti, MD, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, developed a f
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the
- Synairgen’s Inhaled Interferon Beta Cuts Chance of Developing Severe COVID-19 Diseasehttps://modernod.com/news/synairgens-inhaled-interferon-beta-cuts-chance-of-developing-severe-covid-19-disease/2478043/Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalized COVID-19 patients. Chief study investigator Tom Wilkinson remarked “the results confirm our belief tha
- Reports Hint at Positive Data Coming for AstraZeneca, Oxford Coronavirus Vaccinehttps://modernod.com/news/reports-hint-at-positive-data-coming-for-astrazeneca-oxford-coronavirus-vaccine/2478028/Reports emerged that positive news will be released soon on AstraZeneca’s experimental COVID-19 vaccine that it is working on with the University of Oxford. The Lancet has also confirmed that data from a phase 1 trial of AZD1222, formerly known as ChAdOx1 nCoV-19, will be published